

An Economic Evaluation of The Relationship Between Glycemic Control and Total Healthcare Costs for Adults with Type 2 Diabetes: Retrospective Cohort Study

Kristina S Boye, PhD^A
Jay P Bae, PhD^B
Vivian T Thieu, PhD^C
Maureen J Lage, PhD^D

A – Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, 46225, USA. E-Mail: boye_kristina_secnik@lilly.com. ORCID ID: 0000-0002-5935-5929.

B – Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46225, USA. E-Mail: bae_jay@lilly.com. ORCID ID: 0000-0002-2322-1450.

C – Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, 46225, USA. E-Mail: thieu_vivian_thuyanh@lilly.com.

D – Corresponding Author. HealthMetrics Outcomes Research, 17 Benton's Knoll, Guilford, CT, 06437, USA. E-Mail: lagemj@hlthmetrics.com. ORCID ID: 0000-0003-4961-2027.

Supplemental Table 1
Propensity Score Matching
Odds of Index HbA1c < 7%

	Odds Ratio	95% Confidence Interval	Standard Difference^A
Age	1.02	1.02 - 1.03	0.16
Male	0.83	0.80 - 0.85	-0.07
Asian	0.93	0.84 - 1.03	0.01
African-American	0.91	0.87 - 0.95	0.02
Race Other/Unknown	0.95	0.90 - 1.00	0.01
Hispanic	0.73	0.69 - 0.78	-0.02
Ethnicity Unknown	0.89	0.84 - 0.93	0.01
Midwest	1.00	0.96 - 1.04	-0.06
Northeast	0.99	0.94 - 1.04	0.03
West	1.04	0.99 - 1.10	0.01
Year of Index Date	0.99	0.98 - 1.01	0.04
Ratio of Variance of Propensity Score	1.05		
Standardized Difference of Mean Propensity Score	0.16		

A - Standardized difference of covariate of interest for individuals with HbA1c < 7% and individuals with HbA1c ≥ 7% after propensity score matching.